Protaphane (insulin human (rDNA))
- Region
- 🇪🇺 EU
- Active substance
- insulin human (rDNA)
- Company
- Novo Nordisk A/S
- Status
- Authorised
- Therapeutic area
- Diabetes Mellitus
- CHMP opinion
- Thu 25 Apr 2002
- EU approval
- Mon 07 Oct 2002
- Application
- EMEA/H/C/000442
- ATC
- A10AC01
- Official record
- www.ema.europa.eu
Indication
Treatment of diabetes mellitus.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Actraphane Authorised · Novo Nordisk A/S
- 🇪🇺 Mixtard Authorised · Novo Nordisk A/S
- 🇪🇺 Inpremzia Withdrawn · Baxter Holding B.V.
- 🇪🇺 Insulatard Authorised · Novo Nordisk A/S
- 🇪🇺 Velosulin Withdrawn · Novo Nordisk A/S
- 🇪🇺 Monotard Withdrawn · Novo Nordisk A/S
- 🇪🇺 Ultratard Withdrawn · Novo Nordisk A/S
Follow Protaphane
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.